Clinical trials
DM1 clinical trials
Below are recruiting dm1 clinical trials, each written for real people, not researchers. We’re tracking 27 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07700225Recruiting
Long-term study of myotonic dystrophy type 1
This study is a long-term follow-up for people with myotonic dystrophy type 1. It aims to find better ways to measure how the disease progresses, which could help develop future treatments.
Richmond, VirginiaAges 18–70 - NCT07630389Recruiting
Remote monitoring for childhood myotonic dystrophy
This study uses video calls and online assessments to track how myotonic dystrophy (a muscle-weakening condition) affects children over time. Researchers will also look at genetic factors to better understand the disease and improve care.
Rochester, New YorkAges birth–17 years - NCT07008469Enrolling by invitationPhase 3
Long-term safety study of del-desiran for DM1
This study tests whether the drug del-desiran continues to be safe and effective for people with DM1 (myotonic dystrophy type 1) after they complete an earlier study. You'll receive the drug and have regular check-ups to see how you're doing.
Los Angeles, CaliforniaAges 16 years+ - NCT07486934RecruitingPhase 3
Study of DYNE-101 for Myotonic Dystrophy Type 1
This trial tests an experimental drug called DYNE-101 to see if it can help people with myotonic dystrophy type 1 (DM1). The study aims to improve muscle function and daily life. It is for adults who can walk and stand up from a chair without help.
La Jolla, CaliforniaAges 16 years+ - NCT06830889RecruitingPhase 3
BL-M07D1 vs T-DM1 for HER2-positive breast cancer after neoadjuvant therapy
This trial tests whether a new drug called BL-M07D1 works better than an existing drug, T-DM1, for people with HER2-positive breast cancer who still have cancer cells after initial treatment (neoadjuvant therapy). The goal is to prevent the cancer from coming back.
Nanjing, JiangsuAges 18–75 - NCT06846437RecruitingPhase 3
New drug JSKN003 vs. Kadcyla for HER2-positive advanced breast cancer
This trial compares a new targeted therapy (JSKN003) against Kadcyla (T-DM1) for people with HER2-positive breast cancer that has advanced or spread. Both drugs work by attaching a chemotherapy directly to HER2-positive cancer cells, and the study aims to see if the new drug works better or has fewer side effects.
ShanghaiAges 18 years+ - NCT07673029RecruitingPhase 3
Comparing two treatments for HER2-positive breast cancer
This trial compares a new drug, GQ1005, with an existing treatment called T-DM1 for people with HER2-positive breast cancer that has spread or cannot be removed by surgery. The goal is to see which one works better for those who have already received certain other treatments.
Bengbu, AnhuiAges 18–75 - NCT03981575Recruiting
Biomarker and health marker study in myotonic dystrophy type 1
This study measures physical and lab “health markers” in people with myotonic dystrophy type 1 (DM1) to better understand how the disease changes over time. Some participants may also have a muscle biopsy to study tissue differences.
La Jolla, CaliforniaAges 18–70 - NCT04620187RecruitingPhase 2
Study medicine T-DM1 after surgery for HER2-positive salivary cancer
This Phase 2 trial studies T-DM1 given after surgery for salivary gland cancer that is HER2-positive. The goal is to reduce the risk of the cancer coming back by targeting HER2-positive tumor cells.
Atlanta, GeorgiaAges 18 years+ - NCT06272799Recruiting
T-DM1 after incomplete response to initial breast cancer therapy
This trial is for people with HER2-positive breast cancer who still had cancer after initial chemotherapy. It tests the safety and effectiveness of a drug called T-DM1 (Kadcyla) given after surgery to reduce the chance of the cancer coming back.
Rome, RomeAges Any age - NCT07505342Recruiting
Remote study for myotonic dystrophy type 1
This study tests whether remote assessments can track myotonic dystrophy type 1 (DM1) and looks at genetic factors. It aims to find better ways to monitor the disease from home.
Rochester, New YorkAges 18–88 - NCT04893109RecruitingPhase 2
Study compares two HER2 breast cancer treatments after surgery
This Phase 2 study tests two different medicines given after breast surgery to reduce the risk of cancer coming back. It is only for people with early-stage HER2-positive breast cancer with limited or no lymph node spread.
San Francisco, CaliforniaAges 18 years+ - NCT06926621Enrolling by invitationPhase 2
Long-term safety and effectiveness of VX-670 for myotonic dystrophy
This study is for people who already received VX-670 in a previous trial and want to continue treatment. It will check the drug's long-term safety and how well it works for myotonic dystrophy type 1.
St Louis, MissouriAges 18 years+ - NCT06481956Enrolling by invitationPhase 2
T-DM1 plus a CDK4/6 inhibitor (ribociclib) for HER2-positive breast cancer
This clinical trial tests a combination of two targeted therapies for people with HER2-positive breast cancer that has spread or come back. The goal is to see if adding ribociclib to T-DM1 is safe and effective after other treatments have been used.
Hangzhou, ZhejiangAges 18–75 - NCT05224778Recruiting
Study for young children with neonatal myotonic dystrophy type 1
This study looks at measurements and child-focused outcomes in babies and toddlers with myotonic dystrophy type 1 (DM1) that started in the newborn period. It may help researchers better track how the condition affects children and evaluate care plans more accurately.
Los Angeles, CaliforniaAges Up to 4.9 years - NCT05288777RecruitingPhase 2/Phase 3
Testing follow-up chemo and radiation for high-risk breast cancer
This trial studies a standard follow-up treatment plan that combines chemotherapy and radiation after surgery, and it looks for blood/tissue “biomarkers” that predict who benefits most. If you have high-risk breast cancer that didn’t fully disappear after initial (neoadjuvant) chemo, you may be eligible to help guide better future treatment choices.
Charlottesville, VirginiaAges 18 years+ - NCT05481879RecruitingPhase 1/Phase 2
Study medicine for DM1 to improve muscle function
This early-stage study tests DYNE-101 to see how safe it is and whether it can improve measurable muscle function in people with myotonic dystrophy type 1 (DM1). You may be asked to do several walking and strength tests and undergo heart and breathing screening measurements.
Stanford, CaliforniaAges 18–65 - NCT05673928RecruitingPhase 2
Tucatinib and T-DM1 for HER2-positive brain-metastasis tumors
This Phase 2 study tests tucatinib plus T-DM1 (ado-trastuzumab emtansine) in people with HER2-positive metastatic solid tumors that have spread to the brain. It aims to shrink brain and body tumors and help control cancer that is progressing in the brain.
Houston, TexasAges 18 years+ - NCT06300307RecruitingPhase 1/Phase 2
Study of ATX-01 for Myotonic Dystrophy Type 1
This trial tests an experimental drug called ATX-01 for people with myotonic dystrophy type 1 (DM1), a condition that causes muscle weakness and stiffness. The study aims to see if ATX-01 can help reduce symptoms like muscle stiffness (myotonia) and improve daily function.
Los Angeles, CaliforniaAges 18–64 - NCT06439693RecruitingPhase 2
Sequential therapy for newly diagnosed HER2+ breast cancer that has spread
This trial tests a sequence of targeted therapies for people newly diagnosed with HER2-positive breast cancer that has spread to other parts of the body. The goal is to find a treatment plan that can potentially cure the cancer.
Boston, MassachusettsAges 18 years+ - NCT06708468Recruiting
Personalized training for rare neuromuscular disorders
This study tests a personalized exercise program for people with rare neuromuscular diseases like FSHD, DM1, or CMT to see if it improves their physical function and quality of life.
BergenAges 18–70 - NCT06928818Recruiting
T-DM1 after T-DXd for advanced HER2-positive breast cancer
This trial looks at whether a different targeted therapy, T-DM1, can work for women with advanced HER2-positive breast cancer after they have already tried another targeted therapy called T-DXd (Enhertu). If you have progressed while on T-DXd and have not had more than three previous treatments for advanced cancer, you may be able to join.
SeoulAges 19 years+ - NCT07257809RecruitingPhase 2
Herombopag for low platelets from T-DM1 in breast cancer
This trial tests if herombopag can help raise platelet counts in breast cancer patients who have low platelets caused by the drug T-DM1 after prior anti-HER2 therapy. If it works, it may allow you to continue T-DM1 without delays or dose reductions.
Guangzhou, GuangdongAges 18–75 - NCT07385443Recruiting
Spanish registry for myotonic dystrophy type 1
This registry collects information from people with myotonic dystrophy type 1 (DM1) to better understand the condition and improve care. Anyone with a confirmed genetic diagnosis can join.
Multiple Locations, AndalusiaAges Any age
Hear when a new DM1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
DM1 trials by city
Studies with a site in or near these metro areas.
DM1 trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for dm1?
- Yes. Clin2 currently lists 27 recruiting dm1 studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a dm1 trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a dm1 trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.